Mycophenolate mofetil is a prodrug widely used in renal transplantation to prevent organ rejection. It is hydrolyzed to its active compound mycophenolic acid (MPA). MPA area under the curve (AUC) is considered the best pharmacokinetic parameter for the estimation of MPA exposition and for prediction of rejection. MPA-AUC requires several blood samples, making it impractical for clinical practice. Therefore, development of a limited sampling strategy (LSS) to estimate MPA AUC using three blood samples is very helpful for MPA individual dose adjustment. Results of LSS differ according to the patient background and to the drug formulation. Therefore, the purpose of this study was to develop a LSS for the estimation of MPA AUC in Tunisian renal transplant patients treated with the generic formulation of mycophenolate mofetil (MMF, MEDIS). The best correlation was achieved by a profile based on three time points C, C, and C after drug intake: AUC = 0.414 + 1.210 × C + 2.256 × C + 4.134 × C (mei = 1.65% and rmse = 5.81%). The correlation between full AUC and abbreviated AUC was 0.917. In conclusion, this model provides a reliable and simple equation to estimate MPA AUC for the generic formulation of mycophenolate mofetil (MMF).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.nephro.2017.02.010 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!